• In early May 2026, McKesson reported fourth-quarter sales of US$96.30 billion and net income of US$1.68 billion, with full-year sales reaching US$403.43 billion and net income of US$4.76 billion, alongside robust earnings per share growth from continuing operations.
• At the same time, McKesson completed a very large share repurchase program totaling 66.50 million shares for US$21.13 billion, a move that aligns with institutional investors’ focus on its resilient pharmaceutical distribution model, technology investments, and long-term cash generation.
• We’ll now examine how McKesson’s strong earnings performance and extensive share buybacks influence its existing investment narrative and future expectations.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

McKesson Investment Narrative Recap

To own McKesson, you need to believe in the durability of its pharmaceutical distribution platform, supported by growing drug volumes and complex supply chain needs, while watching regulatory pressure on healthcare costs as a key risk. The latest results, with strong earnings and extensive buybacks, reinforce that core thesis but do not materially change the near term focus on execution in technology and value added services.

The completion of McKesson’s US$21.13 billion share repurchase program, covering 66.50 million shares, is especially relevant here because it amplifies the impact of earnings growth on per share metrics. For investors watching catalysts, this capital return sits alongside investments in automation and analytics that are intended to support efficiency and protect margins as the supply chain becomes more complex.

Yet against this strength, the risk that regulators tighten the screws on drug pricing and wholesaler margins is something investors should be aware of...

McKesson's narrative projects $499.3 billion revenue and $6.1 billion earnings by 2029. This requires 7.4% yearly revenue growth and about a $1.3 billion earnings increase from $4.8 billion today.

Uncover how McKesson's forecasts yield a $951.73 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span from about US$2 to US$952 per share, showing how far apart individual views can be. When you set that against McKesson’s reliance on rising pharmaceutical demand and more complex logistics to support growth, it underlines why you may want to compare several viewpoints before deciding how this business fits into your portfolio.

Explore 5 other fair value estimates on McKesson - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your McKesson research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free McKesson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate McKesson's overall financial health at a glance.

Looking For Alternative Opportunities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Capitalize on the AI infrastructure supercycle with our selection of the 44 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.